Clinical Reasoning: A 65-Year-Old Woman With New Headache, Pulsatile Tinnitus, and Visual Disturbances

Laura Donaldson, MD PhD¹, Ryan T. Muir, MD², Joanna D. Schaafsma, MD PhD², Edward Margolin, MD¹,²

Corresponding Author:
Edward Margolin, MD, FRCSC, Dipl. ABO
edmargolin@gmail.com

Affiliations
1. University of Toronto, Department of Ophthalmology and Vision Sciences, Toronto, Ontario, Canada
2. University of Toronto, Department of Medicine, Division of Neurology, Toronto, Ontario, Canada

Manuscript Category: Resident and Fellow Section Clinical Reasoning
Manuscript Word Count: 1476
Conflicts: None of the authors have conflicts to declare
References: 14
Figure 1: Fundoscopy, Visual Fields, Neuroimaging

Study Funding: The authors report no targeted funding
Disclosures: None of the authors have relevant disclosers to submit

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Section 1

A 65 year-old previously healthy woman noticed new onset gradual blurry vision in her left eye with perceived loss of peripheral vision and pulsatile tinnitus in the left ear for the past two weeks. For the past year she visited three different emergency departments (ED) for new non-pulsatile and non-thunderclap headaches, which she described as “searing” pain. The headaches were accompanied by nausea without phono- or photophobia and were not worsened or triggered by recumbency, Valsalva, and did not wake her from sleep. There were no associated neurological or systemic symptoms. A non-contrast computerized tomography (CT) of the brain was interpreted as normal. Visual acuity was 20/25 bilaterally. There was no relative afferent pupillary defect. On ophthalmoscopy she had bilateral severe optic nerve head edema (Figure 1A). Formal visual field testing (Humphrey 24-2) showed enlargement of the blind spots in each eye (Figure 1B). The remaining neurologic examination was normal.

Questions for Consideration:
What are the red flags in this patient’s headache history?
What is the differential diagnosis and next most appropriate imaging study to order?

Section 2

This patient’s presentation with new headaches at an older age, accompanied by blurred vision and pulse-synchronous tinnitus, raise suspicion for increased intracranial pressure (ICP). Ophthalmoscopy can confirm the presence of ICP by identifying optic disc edema. In addition, even when performed correctly, ophthalmoscopy can be difficult to interpret, as common and benign aetiologies can mimic optic disc edema, including optic disc drusen and small, crowded or anomalous optic nerves.

Bilateral optic disc edema with normal visual function in this patient is consistent with papilledema. The differential diagnosis for papilledema is broad, including idiopathic intracranial hypertension, cerebral venous sinus thrombosis (CVST), hydrocephalus, intracranial space-occupying lesions, and meningoencephalitis. Brain parenchymal imaging with MRI or CT including venography should be performed in all patients with suspected papilledema.

Our patient’s CT scan revealed an elongated left styloid process possibly compressing left internal jugular vein (Figure 1C). An elongated styloid process can rarely cause compression of adjacent structures including the carotid artery or jugular vein as it passes between the styloid process and transverse process of the first cervical vertebrae and can be associated with ischemic events and tinnitus (“vascular Eagle syndrome”).

MR venography revealed complete opacification of right transverse and sigmoid sinuses with high T2/FLAIR hyperintense signal within opacified areas without corresponding high signal on T1, consistent with extensive chronic thrombosis. There was also a non-occlusive filling defect in left sigmoid sinus and jugular vein (Figure 1D-F). A lumbar puncture to measure the ICP demonstrated an opening pressure of 47 cm of water with
normal CSF composition. No infectious etiology was identified. Her remaining bloodwork revealed an elevated hemoglobin of 168 g/L (120-160g/L) and hematocrit of 0.52 (0.38-0.50).

Digital subtraction angiography (DSA) was performed to assess the degree of stenosis and pressure gradient across dural venous sinuses, to exclude the presence of dural arteriovenous fistula (DAVF) and, given her elongated styloid process, to assess the effect of provocative maneuvers (head-turning) on venous outflow. DSA demonstrated severe stenosis of left jugular bulb and both right transverse and sigmoid sinuses, resulting in severe venous hypertension. Head turning decreased venous outflow although the area of worst stenosis was located above the level of the styloid process.

Treatment with oral anticoagulation was initiated and to decrease ICP, acetazolamide was initiated with close neuro-ophthalmic follow up.

**Question for consideration:**

Do you think the elongated styloid process is causative?

What additional investigations would you order?

**Section 3**

One possible interpretation of our patient's presentation is that jugular vein compression by an elongated styloid process could promote venous stasis, predisposing to thrombosis formation. However, while imaging demonstrated an elongated left styloid process, the evidence for it being the culprit for CVST was not definitive on DSA and thrombosis was more extensive on the right side and the measured styloid length was near the upper limit of normal. Therefore, an alternate diagnosis was pursued.

Recent European guidelines do not recommend screening for occult malignancy or thrombophilia in patients with CVST. However, given her extensive unprovoked thrombosis and elevated hemoglobin/hematocrit, hypercoagulability screening was performed, including Factor V Leiden, protein C/S, homocysteine, antiphospholipid and anticardiolipin antibodies, prothrombin and JAK2 (Janus kinase 2) mutations.

Ultimately, testing for prothrombotic JAK2 V617F mutation was positive.

**Question for consideration:**

1. Given this result, what further investigations should now be performed?
2. What should the patient be told regarding her future risk of thrombotic events?

**Section 4**

The JAK2 V617F substitution is a driver mutation in myeloproliferative neoplasms and is present in nearly all cases of polycythemia vera (PV) and 50-60% of cases of primary myelofibrosis and essential thrombocytosis. Our patient had a hemoglobin of 168 g/L, which had increased from 139 g/L one year prior. There was also mild thrombocytosis.
with platelet count 435 (150-400) compared to her prior count of 337. A bone marrow biopsy demonstrated hypercellularity with panmyelosis and atypical cells which was diagnostic of PV. Treatment with hydroxyurea was recommended but was declined by the patient thus serial phlebotomies were used as an alternate treatment strategy.

JAK2 V617F is associated with a increased risk of thrombotic events both in carriers and in patients with myeloproliferative neoplasms, thus necessitating long-term treatment with direct oral anti-coagulation. Over the next year her papilledema resolved and follow up venography demonstrated recanalization at the site of previous CVST.

**Discussion**

This clinical reasoning case is one of the few reports of CVST arising due to JAK2 V617F mutation – an underappreciated etiology and diagnostic consideration of CVST. Testing for JAK2 mutation must be performed in all CVST patients with elevated hemoglobin and should be considered even in those with normal CBC.

While well-appearing patients with papilledema are often presumed to have idiopathic intracranial hypertension (IIH), it is a diagnosis of exclusion and requires normal neuroimaging with venography (excluding indirect signs of raised ICP), normal CSF analysis, and no neurologic deficits beyond a sixth nerve palsy. This patient was not in the typical demographic group for IIH as only around 5 percent of patients are over the age of 50 at diagnosis. Venography should be performed in all patients with papilledema who are not in a typical group for IIH (and some would argue it should be performed in all) as CVST is a relatively common secondary cause of raised ICP.

Venous stasis forms with vessel wall injury and hypercoagulability Virchow’s triad responsible for development of venous thrombosis. Although CVST is not commonly seen in Eagle syndrome, it has been reported in some with styloido-jugular compression with high pressure gradients across the region of venous compression with resolution post-styloidectomy. Styloidectomy was considered in this case, however, when the JAK2 mutation and bone marrow biopsy confirmed PV, non-invasive treatment with anticoagulation and serial phlebotomies commenced. While it is unclear whether the elongated styloid process contributed to CVST in our patient, we hypothesize that the combination of her underlying hypercoagulable state and venous stasis produced by an elongated styloid process together increased her risk of developing CVST.

The pathophysiology of hypercoagulable states in patients with JAK2 V617F mutation is multifactorial. In patients with overt myeloproliferative neoplasms, hyperviscosity is a probable contributor. However, the mutation alone carries an increased risk of thrombosis. One additional mechanism for thrombus formation is abnormal neutrophil activation leading to altered cell adhesion and binding of platelets and leukocytes to vascular endothelium.

The evidence regarding optimal duration of anticoagulation after initial treatment of CVST with low molecular weight heparin is not clear and the general recommendation is between 3 and 12 months. In patients with PV, the risk for recurrent thrombosis must be managed and cytoreductive therapy such as hydroxyurea is recommended in older PV patients or in those with a previous thrombotic event. As our patient declined hydroxyurea, phlebotomy and long-term anticoagulation with apixaban were chosen.
Although comparative safety and efficacy of direct oral anticoagulants (DOACs) versus warfarin has not yet been established in randomized control trials for patients with chronic CVST, emerging evidence suggests that both are effective in preventing recurrence.\textsuperscript{15} DOACs are increasingly used due to their convenience and favourable pharmacologic properties.

This clinical reasoning case is unique as it highlights an underappreciated diagnostic etiology of CVST: JAK2 mutation. We underline unique clinical characteristics of patients with JAK2 mutation and describe the clinical reasoning that led to a correct diagnosis and management in our patient. Recognition of optic disc edema was paramount in this case highlighting the importance of ophthalmoscopy in evaluating patients with headaches, and underpinning the importance of collaborative relationships between neurologists and neuro-ophthalmologists. In this case, even though some degree of unilateral jugular vein compression by an elongated styloid process may have contributed to an upstream vulnerable milieu of cerebral venous stasis and was a tempting initial explanation for thrombosis, a hypercoagulable work-up revealed that a prothrombotic mutation in JAK2 was the most likely underlying cause of CVST.

References


Copyright © 2021 American Academy of Neurology. Unauthorized reproduction of this article is prohibited
Figure Legend

Figure 1. Papilledema secondary to cerebral venous sinus thrombosis. A) Fundus photographs demonstrating bilateral optic disc edema. B) Humphrey Visual Fields (24-2 algorithm) demonstrating blind spot enlargement in the right eye. C) Coronal contrast-enhanced CT head showing compression of left internal jugular vein by elongated styloid process (black arrow). D) MR venography, coronal view demonstrating non-visualization of the right distal transverse sinus, sigmoid sinus and internal jugular vein (white arrowheads) with filling defect due to thrombus within the left internal jugular vein (white arrow). E) Sagittal MR venography image demonstrating barely visible right internal jugular vein (white arrow). F) Sagittal MR venography image demonstrating thin, non-occlusive thrombus in left internal jugular vein (white arrow).
<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Donaldson, MD, PhD</td>
<td>Department of Ophthalmology and Vision Science, University of Toronto</td>
<td>Wrote manuscript</td>
</tr>
<tr>
<td>Ryan T. Muir, MD</td>
<td>Department of Medicine, Division of Neurology, University of Toronto</td>
<td>Revised manuscript for intellectual contribution</td>
</tr>
<tr>
<td>Joanna D Schaafsma, MD, PhD</td>
<td>Department of Medicine, Division of Neurology, University of Toronto</td>
<td>Revised manuscript for intellectual contribution</td>
</tr>
<tr>
<td>Edward Margolin, MD</td>
<td>Department of Ophthalmology and Vision Science, and Department of Neurology, University of Toronto</td>
<td>Wrote manuscript</td>
</tr>
</tbody>
</table>
Clinical Reasoning: A 65-Year-Old Woman With New Headache, Pulsatile Tinnitus, and Visual Disturbances
Laura Donaldson, Ryan T. Muir, Joanna D. Schaafsma, et al.

*Neurology* published online July 29, 2021
DOI 10.1212/WNL.0000000000012575

This information is current as of July 29, 2021

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://n.neurology.org/content/early/2021/07/29/WNL.0000000000012575.citation.full">http://n.neurology.org/content/early/2021/07/29/WNL.0000000000012575.citation.full</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td>- Cerebral venous thrombosis</td>
</tr>
<tr>
<td></td>
<td><a href="http://n.neurology.org/cgi/collection/cerebral_venous_thrombosis">http://n.neurology.org/cgi/collection/cerebral_venous_thrombosis</a></td>
</tr>
<tr>
<td></td>
<td>- Clinical neurology examination</td>
</tr>
<tr>
<td></td>
<td><a href="http://n.neurology.org/cgi/collection/clinical_neurology_examination">http://n.neurology.org/cgi/collection/clinical_neurology_examination</a></td>
</tr>
<tr>
<td></td>
<td>- Optic nerve</td>
</tr>
<tr>
<td></td>
<td><a href="http://n.neurology.org/cgi/collection/optic_nerve">http://n.neurology.org/cgi/collection/optic_nerve</a></td>
</tr>
<tr>
<td></td>
<td>- Secondary headache disorders</td>
</tr>
<tr>
<td></td>
<td><a href="http://n.neurology.org/cgi/collection/secondary_headache_disorders">http://n.neurology.org/cgi/collection/secondary_headache_disorders</a></td>
</tr>
<tr>
<td></td>
<td>- Visual fields</td>
</tr>
<tr>
<td></td>
<td><a href="http://n.neurology.org/cgi/collection/visual_fields">http://n.neurology.org/cgi/collection/visual_fields</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online:</td>
</tr>
<tr>
<td></td>
<td><a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>